Burns - Pipeline Review, Q2 2011

Burns - Pipeline Review, Q2 2011

Summary

Global Markets Direct’s, 'Burns - Pipeline Review, Q2 2011', provides an overview of the Burns therapeutic pipeline. This report provides information on the therapeutic development for Burns, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Burns. 'Burns - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Burns.
- A review of the Burns products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Burns pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Burns.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Burns pipeline depth and focus of Burns therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. SHOW LESS READ MORE >

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Burns Overview
Therapeutics Development
An Overview of Pipeline Products for Burns
Burns Therapeutics under Development by Companies
Burns Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Burns Therapeutics - Products under Development by Companies
Burns Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Burns Therapeutics Development
CytoTools AG
Digna Biotech, S.L.
Healthpoint, Ltd.
Glycotex, Inc.
NanoBio Corporation
American Scitech Inc.
Burns - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
P144 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mebo - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ICX-SKN - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GLYC- 101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DermaPro Pep04 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Opebacan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Amnion - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Caspofungin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Heparin Sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Alimax - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sulfamylon - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Silver Nitrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dakins Solution - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rhPDGF-BB - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cultured Autologous Keratinocytes - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Interferon Alpha 2b - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KUR-212 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NB-201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Levamizole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Propranolol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cerium Solution - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Amnion Derived Cellular Cytokine Solution - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Burns Therapeutics – Drug Profile Updates
Burns Therapeutics - Discontinued Products
Burns - Featured News
Oct 12, 2010: Nanobio And The University Of Michigan Awarded $1.5M Department Of Defense Grant To Study Topical Anti-Infective Treatment For Combat Related Injuries
Sep 14, 2009: NanoBio Presents Key Data On The Use Of Nanoemulsions To Treat Burn Wound Infections
Aug 12, 2009: Kuros Announces Encouraging Phase IIa Data With KUR-212 In Patients With Burns Requiring Mesh Grafting
Aug 11, 2008: Kuros Announces Results Of One-Month Follow-Up Of Phase IIa Trial Of KUR-212 In Patients With Burns Requiring Mesh Grafting
Feb 04, 2008: Kuros Completes Patient Recruitment In Phase Lia Trial Of KUR 212 In Patients With Severe Burns Requiring Meshed Skin Grafting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Burns, Q2 2011
Products under Development for Burns – Comparative Analysis, Q2 2011
Number of Products under Development by Companies, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Comparative Analysis by Late Stage Development, Q2 2011
Comparative Analysis by Mid Clinical Stage Development, Q2 2011
Comparative Analysis by Early Clinical Stage Development, Q2 2011
Comparative Analysis by Pre-Clinical Stage Development, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
CytoTools AG, 2011
Digna Biotech, S.L., 2011
Healthpoint, Ltd., 2011
Glycotex, Inc., 2011
NanoBio Corporation, 2011
American Scitech Inc., 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Burns Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Burns, Q2 2011
Products under Development for Burns – Comparative Analysis, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Late Stage Products, Q2 2011
Mid Clinical Stage Products, Q2 2011
Early Clinical Stage Products, Q2 2011
Pre-Clinical Stage Products, Q2 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Route of Administration, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Assessment by Stage and Molecule Type, Q2 2011